Molbio Diagnostics Eyes ₹200 Cr via IPO Amid Global Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics industry, is set to raise ₹200 crore through a fresh issue of shares to bolster its capital expenditures. In conjunction with this, the company plans to reduce its promoter stake from 46.6% to 43% by generating an additional ₹740 crore via an offer for sale. This strategic financial maneuver aims to support Molbio's ongoing expansion and operational capabilities.

Global Reach and Product Portfolio

Founded in 2000, Molbio Diagnostics has established a significant global footprint with six manufacturing facilities across India, serving customers in over 90 countries. The company’s diagnostic solutions are widely used in government health programs, diagnostic laboratories, hospitals, and various international healthcare organizations. One of Molbio's flagship products is the 'Truenat' platform, a portable diagnostic system capable of delivering accurate test results within an hour, designed specifically for resource-limited settings.

The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays. Its subsidiaries and strategic collaborations further enhance its offerings, which include radiology, digital pathology, and breast health screening solutions. A substantial portion of Molbio's revenue, approximately 74%, is derived from test kit sales, with tuberculosis diagnostic kits contributing significantly.

Financial Performance and Market Position

Molbio has demonstrated robust financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, net profit surged by 40.2% to ₹164.1 crore, while EBITDA rose by 33.2% to ₹328.2 crore, reflecting an EBITDA margin improvement from 22% in FY24 to 22.6% in FY26. In FY26 alone, revenue jumped 41.7%, EBITDA grew 27.9%, and net profit increased by 18.4%.

The company's valuation, based on post-IPO equity and net profit for FY26, suggests a price-earnings (P/E) multiple of up to 57. While Molbio lacks directly comparable listed peers in India, other healthcare diagnostics and medical device firms like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre trade at P/E multiples ranging from 54 to 81.

Investor Considerations

With its substantial revenue growth and strategic investments in expanding its diagnostic capabilities, Molbio Diagnostics presents an intriguing opportunity for high-risk investors seeking long-term growth. However, potential investors should be aware of the company's customer concentration, as a significant portion of its revenue is tied to a few key clients. Additionally, over four-fifths of its revenue is linked to government and international aid agencies, which could pose risks related to policy changes and funding fluctuations.